乳腺良恶性病变组织端粒长度和端粒酶活性检测

Telomere length and telomerase activity in benign and malignant breast tumor

目的 比较乳腺良恶性病变端粒长度改变及其在肿瘤发生发展中的意义 ;探讨端粒酶活性与临床病理参数的关系及其在乳腺癌诊断中的价值。方法 Southern印迹杂交检测TRF长度 ,端粒重复扩增分析 (TRAP)方法检测端粒酶活性。结果 乳腺癌组织平均TRF为 (5 2± 2 8)kb ,与正常组织比较明显缩短 (P <0 0 0 1) ,从正常乳腺组织到乳腺良性病变、乳腺原位癌及浸润性癌平均TRF呈递减趋势。 5 8例乳腺癌中 4 9例端粒酶阳性 (84 7% ) ,端粒酶活性与临床病理参数无相关性 ;癌旁组织端粒酶为阴性 ,而 7例乳腺增生症和 6例乳腺纤维腺瘤中分别有 1例端粒酶阳性 ,与乳腺癌比其差异有显著性 (P <0 0 0 1)。结论 端粒长度在肿瘤发生发展过程中渐进性缩短 ,并最终触发端粒酶的激活 ;

Purpose To study the significance of telomere length alteration in carcinogenesis and the relationship of telomerase activity with clinicopathological parameters and it's value in diagnsis of breast cancer. Methods Telomeric restriction fragment (TRF) length were measured by Southern blot analysis. Telomerase activity were detected by telomeric repeat amplification protocol (TRAP) method. Results The mean TRF length of breast cancer was (5.2±2.8) kb, and was significantly shortened comparing to adjacent noncancerous tissue (P<0.001). The mean TRF length showed tendency of decreasing progressively from normal tissue to benign breast lesions to in situ carcinoma to invasive carcinoma. Telomerase activity was detected in 49 of 58 (84.7%) cases of breast cancer by TRAP method. There was no correlation between telomerase activity and clinical pathology parameters. The telomerase activity of adjacent noncancerous tissue was absent, while the activity was detected in 1 of 6 (16.7%) fibroadenomas and 1 of 7 (14.3%) fibrocystic disease., they all exhibited significant differences comparing with breast carcinomas (P<0.001) . Conclusions Telomere shortened gradually in the development of tumors and triggered the activation of telomerase. Detection of telomerase activity by TRAP method is useful in the diagnosis of malignant tumors.